Tsuyoshi Maekawa

This inventor holds 17 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 1 EPO patent, primarily in Heterocyclic Compounds. Top assignees: Takeda Pharmaceutical Company Limited, Scohia Pharma, Inc.. Active years: 2006-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tsuyoshi Maekawa. Retrieved from https://idiyas.com/inventor/tsuyoshi-maekawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 17.6

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 102(Granted Patents)

Location History:

Nara, JP (2006 - 2007)
Osaka, JP (2008 - 2015)
Kanagawa, JP (2016 - 2022)

Company Filing History:

16 out of 1,233

Takeda Pharmaceutical Company Limited

where one patent can have more than one assignee

Years Active: 2006-2022

Loading Chart...

Areas of Expertise:

Macrocyclic Compound

Aromatic Compound

Cyclyl-Acetic Acid Derivatives

Benzimidazole Derivatives

Fused Ring Compound

Substituted Pyrimidines

Triazoles

Heteromonocyclic Compound

Antihypertensive Action

Five-Membered Heterocyclic Compounds

Hypoglycemic Activity

Isoxazole Derivatives

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11518763 - Macrocyclic compound and use thereof (2022-12-06),

2. 11186565 - Aromatic compound (2021-11-30),

3. 10968231 - Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders (2021-04-06),

4. 9365540 - Benzimidazole derivatives as MCH receptor antagonists (2016-06-14),

5. 9115136 - Fused ring compound and use thereof (2015-08-25),

6. 8921379 - Fused ring compound and use thereof (2014-12-30),

7. 8592431 - Fused ring compound and use thereof (2013-11-26),

8. 8283353 - Fused ring compound and use thereof (2012-10-09),

9. 7998968 - Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases (2011-08-16),

10. 7803940 - Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases (2010-09-28),

11. 7423159 - Agent for preventing or treating neuropathy (2008-09-09),

12. 7368578 - Five-membered heterocyclic compounds (2008-05-06),

13. 7241785 - Five-membered heterocyclic alkanoic acid derivative (2007-07-10),

14. 7238716 - Alkanoic acid derivatives process for their production and use thereof (2007-07-03),

15. 7223791 - Function regulator for retinoid relative receptor (2007-05-29),

Title: **Inventor Spotlight: Tsuyoshi Maekawa from Osaka, JP**

Introduction

Tsuyoshi Maekawa is a prolific inventor based in Osaka, Japan, known for his significant contributions to the field of pharmaceuticals and medicinal chemistry. With a total of 17 patents to his name, Maekawa's work focuses on developing innovative compounds with potential therapeutic applications.

Latest Patents

Among his latest patents, two stand out for their potential impact on treating serious health conditions. The first is focused on a macrocyclic compound that demonstrates NRF2 activating activity, making it a promising candidate for developing preventive or therapeutic agents for diseases linked to oxidative stress, such as non-alcoholic steatohepatitis (NASH), cardiovascular diseases, and various other conditions including lung disease, kidney disease, and cancers. The second patent details a novel aromatic compound that showcases GPR40 agonist activity and GLP-1 secretagogue action. This compound may offer therapeutic benefits for conditions like obesity, diabetes, and metabolic syndrome.

Career Highlights

Throughout his career, Tsuyoshi Maekawa has worked with leading pharmaceutical companies, including Takeda Pharmaceutical Company Limited and Scohia Pharma, Inc. His experience within these organizations has undoubtedly contributed to the development of his innovative compounds that target critical health issues.

Collaborations

Maekawa has collaborated with notable coworkers, such as Hideyuki Igawa and Yu Momose, enhancing the research and development efforts in his projects. These collaborations highlight the collective effort involved in advancing medical science through innovation.

Conclusion

Tsuyoshi Maekawa's dedication to developing groundbreaking pharmaceutical compounds places him at the forefront of medical research in Japan. His numerous patents not only reflect his inventive capabilities but also offer hope for new treatments addressing some of the most pressing health challenges today.

Profile summary based on public USPTO records.